[Somatostatin deficiency, hyperinsulinism and thrombocyte aggregation in psoriasis].
In 59 patients suffering from chronic psoriasis, we tested the therapeutic effects of yohimbine and colchicine. It is well known that yohimbine, an alpha 2-adrenoceptor-blocking agent, reduces the secretion of insulin and the platelet factors. 85% of our psoriatic patients showed decreased values for somatostatin, in association with hyperinsulinemia (88%) and low platelet counts. Successful therapy with yohimbine resulted in the normalization of the pathological blood levels.
D002986:Clinical Trials as Topic; D003078:Colchicine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood*; D010974:Platelet Aggregation / Q000187:drug effects*; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy*; D011897:Random Allocation; D013004:Somatostatin / Q000172:deficiency*; D015016:Yohimbine / Q000627:therapeutic use*
D007328:Insulin; D015016:Yohimbine; D013004:Somatostatin; D003078:Colchicine
Somatostatinmangel, Hyperinsulinismus und Thrombozytenaggregation bei Psoriasis.